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Inhibition ofthe growth oftransformed and neoplastic cells by the dipeptide
carnosine
R Holliday and GA McFarland
CSIRO Division ofBiomolecular Engineering, Sydney Laboratory, PO Box 184, North Ryde, NSW 2113, Sydney, Australia.
Summary Human diploid fibroblasts grow normally in medium containing physiological concentrations of the
naturally occurring dipeptide carnosine (fi-alanyl-L-histidine). These concentrations are cytotoxic to
transformed and neoplastic cells lines in modified Eagle medium (MEM), whereas these cells grow vigorously
in Dulbecco's modified Eagle medium (DMEM) containing carnosine. This difference is due to the presence of
1 mM sodium pyruvate in DMEM. Seven human cell lines and two rodent cell lines were tested and all are
strongly inhibited by carnosine in the absence of pyruvate. Experiments with HeLa cells show that anserine is
similar to carnosine, but D-carnosine and homocarnosine are without effect. Also, the non-essential amino
acids alanine and glutamic acid contribute to the effect of pyruvate in preventing carnosine toxicity, and
oxaloacetate and a-ketoglutarate can substitute for pyruvate. We have used mixtures of normal MRC-5
fibroblasts and HeLa cells to demonstrate that 20 mM carnosine can selectively eliminate the tumour cells. This
has obvious implications which might be exploited in in vivo and in vitro studies. Carnosine is known to react
strongly with aldehyde and keto groups of sugars by the Amadori reaction, and we propose that it depletes
certain glycolysis intermediates. It is well known that tumour cells are more dependent on glycolysis than
normal cells. A reduction of glycolysis intermediates by carnosine may deplete their energy supply, but this
effect is totally reversed by pyruvate.
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The dipeptide carnosine (fl-alanyl-L-histidine) is widely
distributed in mammalian tissues. It is synthesised by
carnosine synthetase from its component amino acids and
degraded by carnosinase. There have been many theories
about its biological function, but none have been sub-
stantiated (reviewed by Quinn et al., 1992, and see
Discussion). We previously showed that normal diploid
human fibroblasts can grow in high concentrations of
carnosine (20 mM-50 mM). Moreover, carnosine treatment
can extend the lifespan of these cells and prevent the
appearance of the usual signs of late-passage senescence
(McFarland and Holliday, 1994). In the course of these
studies we also observed that transformed rodent cell lines,
such as 3T3 or CHO, were inhibited by concentrations of
carnosine which did not affect diploid cells. This effect was
media-dependent, in particular, it was evident that carnosine
inhibition of transformed cells was clearly seen in standard
MEM (minimum essential medium), but not in DMEM
(Dulbecco's modification of MEM). We have followed up
these preliminary studies with more detailed investigations of
the effects of carnosine on transformed or tumour cell lines
and have demonstrated a strong interaction between
carnosine and pyruvate. In the absence of pyruvate,
physiological concentrations of carnosine are cytotoxic to
these cells, but cell growth is normal in medium containing
both carnosine and pyruvate. We have used carnosine as a
selective agent which can eliminate HeLa cells from a mixed
population of these and diploid human fibroblasts.
Materials and methods
Cell lines
The permanent cell lines used are listed in Table I. A549 and
TE85 were kindly provided by Dr Roger Reddel (Children's
Medical Research Institute, Westmead Hospital, Sydney,
Australia), BL-17/23a and PC3 by Dr Pam Russell
(Oncology Research Centre, University of New South
Wales, Australia) and WEHI 164 by Dr Larissa Belov
(Peptide Technology, Sydney, Australia). Normal MRC-5
and HFF-1 fibroblasts were also used (see McFarland and
Holliday, 1994).
Cell culture
Three basic media were used: MEM, DMEM and RPMI, all
from Gibco. Media were supplemented with 10% fetal calf
serum (FCS), with 60 Mg ml-' penicillin and 100 jMg ml-'
streptomycin. MEM was supplemented with non-essential
amino acids (NEA) from Cytosystems. Dialysed FCS was
prepared as follows: Spectra/Por membrane tubing (MW cut-
off 6000-8000) was cut into lengths and boiled with three
changes of distilled water. Aliquots of 20 ml FCS were put
into each tube and dialysed overnight against 11 of Hanks'
balanced salt solution at 4°C. This was repeated five times.
The serum was sterilised by filtration.
Cells were grown in 25 cm2 flasks or in 24-well trays and
incubated at 37°C with 5% carbon dioxide. Cells were
harvested with trypsin/versene (T/V), and single cell
suspensions were counted with a ZF6 Coulter counter.
Short-term growth experiments with HeLa cells or other
cells were carried out as follows: 104 cells were inoculated
into 1 ml medium per well in 24-well trays; cells were counted
after 3-4 and 5-7 days by washing with phosphate-buffered
saline (PBS), adding 0.2 ml T/V followed by 0.8 ml of MEM
with complete dispersal of cells with a 1 ml Gilson pipette.
To determine cell survival CHO cells were grown in MEM
with 10% dialysed FCS, 1 mM proline with different
concentrations of carnosine. Either 104 cells were added to
1 ml of medium in 24-well trays or 3 x 104 cells were added to
3 ml of medium in 35 mm dishes. After 24 h incubation, the
attached cells were trypsinised and plated at appropriate
dilutions in 10 ml of MEM in 90 mm dishes. Colonies were
stained with Giemsa after 7 days.
HeLa cells were treated in the same way except for the
substitution of 1 mM serine for proline. Trypsinised cells were
serially diluted in 24-well trays, each well containing 1 ml
MEM. Colonies were grown for 6-7 days, stained with
Giemsa and counted with an inverted microscope. Colonies
of < 10 cells were not counted (see Results section).
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Table I Transformed or neoplastic cell lines used in the experiments with carnosine
Designation Origin Reference
Human
MRC-5V1 SV40-transformed MRC-5 fibroblasts Huschtscha and Holliday (1983)
MRC-5V2 SV40-transformed MRC-5 fibroblasts Huschtscha and Holliday (1983)
HeLa S3 Cervical carcinoma Laboratory stock
A549 Lung carcinoma Giard et al. (1973)
TE85 Osteogenic sarcoma Rhim et al. (1975)
BL- 17/23a Bladder carcinoma Russell et al. (1988)
PC3 Prostate carcinoma Kaighn et al. (1979)
Rodent
CHO K1 Transformed hamster ovary fibroblasts Laboratory stock
WEHI 164 Mouse fibrosarcoma Rollinghoff and Warner (1973)
Chemicals
Carnosine and homocarnosine were obtained from Sigma
Chemical. This was also the source of all organic acids (as
sodium salts) and all amino acids. Anserine (Sigma) and D-
carnosine were gifts from Peptide Technology, Sydney,
Australia. Tenilsetam was a gift from Dr Gerald Munch
(Theodor Boveri Institute, University of Wurzburg, Ger-
many).
Assay for pyruvate
Quantitative enzymatic determination of pyruvate levels in
serum were carried out using the Sigma Diagnostic Pyruvate
Kit procedure. UV absorption at 340 nm was measured with
a Varian DMS 90 UV spectrophotometer.
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Results
SV40 transformed MRC-5 cells
The SV40 transformed derivative of MRC-5, MRC-5V1, has
been fully characterised (Huschtscha and Holliday, 1983).
This immortalised cell line has the usual features of a
transformed cell but it is not tumorigenic in nude mice.
MRC-5V1 cells grow normally in DMEM containing high
concentrations ofcarnosine, as shown in Figure la. However,
in MEM containing 20 mM carnosine, some initial growth
was followed by no further cell division or subculture (Figure
lb). This was a cytotoxic effect, since the treated cells did not
reattach and grow in unsupplemented MEM.
DMEM is a richer medium than MEM, in that it contains
0.45% glucose instead of 0.1% glucose; it has both essential
and non-essential amino acids and higher levels of some
vitamins. It also has added Fe3+. None of these differences
accounted for results like those seen in Figure la and b.
DMEM also contains 1 mM sodium pyruvate, whereas MEM
contains none. Addition of pyruvate to MEM allowed MRC-
5V1 cells to grow in high concentrations of carnosine, as
shown in Figure lb.
HeLa cells
The inhibitory effects of carnosine and its interaction with
pyruvate was explored more fully with HeLa cells. Again, the
difference between MEM and DMEM containing carnosine
was demonstrated. HeLa cells grow in DMEM containing up
to 40 mM carnosine, whilst MEM containing 20 mm was
strongly inhibitory, although in this case the cells survive and
grow very slowly. It was found that the substitution of
dialysed FCS for normal FCS greatly increased the effect of
carnosine, since 15 mM or 20 mM was cytotoxic. This
suggested that pyruvate in FCS might be counteracting the
effect of carnosine, so the possibility was explored in
quantitative experiments in which the concentration of
pyruvate was varied. One such experiment is shown in
Figure 2. However, the difference between FCS and dialysed
FCS cannot be solely attributed to pyruvate in the former. A
direct assay showed that pyruvic acid in FCS was 1.84 ,ug
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Figure 1 MRC-5V1 cells were grown in 25 cm2 flasks and split
1:4 or 1:8 at confluence. Cumulative population doublings were
calculated from the cell count at each split. (a) DMEM with and
without carnosine. (b) MEM with 20 mM carnosine, with and
without 1 mm sodium pyruvate, together with an unsupplemented
control.
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ml-1 (approximately 20 gM) which is not sufficient to;account
for the slow growth of HeLa cells in 20 mM carnosine in
MEM plus 10% FCS.
Further experiments demonstrated the importance of non-
essential amino acids (NEA). The HeLa cell line used in these
experiments grows very slowly in MEM with 10% dialysed
FCS without NEA, but the addition of 1 mM serine or 1 mM
glycine (which are components of NEA) allows normal
growth. It was also discovered that the interaction of
carnosine and pyruvate was strongly affected by alanine or
glutamic acid (as sodium glutamate) which are present in
NEA. In the presence of 1 mM alanine, approximately 0.5
mM pyruvate allows normal growth of HeLa cells in 20 mM
carnosine (Figure 2). However, in the absence of alanine, 2
mM pyruvate is required for normal growth (results not
shown). Glutamate has a very similar effect to alanine, but
the other components of NEA did not interact with pyruvate.
We conclude from these experiments that the interactions of
low molecular weight components of serum, especially
pyruvate and amino acids such as alanine and glutamate,
account for the differences between FCS and dialysed FCS
which we have documented. In the absence of pyruvate, the
strongest toxic affect of carnosine on HeLa cells is seen in
MEM lacking NEA, and supplemented with 1 mM serine and
10% dialysed FCS. The cells grow slowly in 10 mM carnosine
and are completely inhibited by 15 mM or higher
concentrations.
Although the differences between MEM and DMEM
containing carnosine are largely due to pyruvate, there is also
some effect of glucose. Carnosine is more inhibitory in MEM
which has 0.1% glucose, than MEM containing 0.45%
glucose, which is the concentration in DMEM (results not
shown).
Effects of carnosine on other transformed cell lines
As well as MRC-5V1 and HeLa, we have examined MRC-
5V2 and four other human cancer cell lines, and two rodent
cell lines (see Table I). In some cases RPMI is the
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Figure 2 HeLa cells grown in 24-well trays for 5 days in MEM
supplemented with 20 mM carnosine and increasing sodium
pyruvate. 0, MEM with 10% FCS and NEA. 0, MEM with
10% dialysed FCS and NEA. Each well was inoculated with 104
cells (arrowed). This experiment was repeated many times with
the same result.
recommended medium. This is a richer medium than
MEM, but does not contain pyruvate. All cell lines grow in
high levels of carnosine provided 1 mM pyruvate is present.
However, in the absence of pyruvate, carnosine inhibits
growth with some variation in its inhibitory effect. In some
cases 20 mM carnosine in normal MEM or RPMI is
inhibitory, but in others it is necessary to substitute dialysed
FCS for normal FCS or to omit NEA. These results are
summarised in Table II, which indicates the concentration of
carnosine which will inhibit growth and the medium used.
Effects of related dipeptides
Anserine is a modified form of carnosine (P-alanyl-L-methyl
histidine), which is present in avian tissues and some
mammals. Homocarnosine (y-amino butyric acid-L-histidine)
has an additional -CH2 in comparison to f-alanine. D-
carnosine contains D-histidine. Of these three dipeptides (at
20 mM), only anserine inhibited the growth of HeLa cells.
The inhibition was abolished by the addition ofpyruvate. We
also tested the amino acid components of carnosine. A dose
of 20 mM ,B-alanine is not inhibitory, whereas 20 mM
histidine is toxic both in MEM and DMEM. In neither
case is there any interaction with pyruvate.
The strong difference between L-carnosine and D-carnosine
is documented in Figure 3. The result strongly suggests that
the biological function of L-carnosine is in some way related
to its toxicity to tumour cells. This may depend on the
metabolism of L-carnosine within the cell and the lack of
uptake of D-carnosine.
Tricarboxylic acid cycle (TCA) intermediates
Pyruvate is the end product of glycolysis. It can then be
converted to lactic acid during anaerobic metabolism, or it is
converted to acetyl CoA, which feeds into the TCA cycle to
generate ATP by aerobic respiration. We have examined all
TCA intermediates for their effect on carnosine and the
carnosine inhibition of HeLa cells. These results are shown in
Table III. Alpha-ketoglutarate and oxaloacetate have an
effect very similar to pyruvate but none of the other
intermediates has any effect. Alanine, which can be
converted to pyruvate, is inactive as previously mentioned.
Glutamate, which can be converted to a-ketoglutarate is also
ineffective. However, both these amino acids have synergistic
interactions with pyruvate.
Comparison with untransformed cells
In addition to fetal lung fibroblasts, strain MRC-5, we had
previously examined the effects of carnosine on foreskin
fibroblasts, strain HFF-1. Both grow normally in MEM and
DMEM supplemented with 20 mM carnosine. They also grow
in DMEM containing 30 mM carnosine, and HFF-1 grows
slowly in DMEM containing 50 mM carnosine. MRC-5 is
Table H The lowest concentration of carnosine which inhibits
growth of cell lines
Cell line Medium used
MRC-5V1 20 mM in MEM
MRC-5V2 30 mM in MEM with dialysed FCS
HeLa S3 15 mM in MEM with dialysed FCS
A549 20 mM in RPMI
TE85 20 mM in RPMI or MEM
BL-17/23a 20 mM in RPMI
PC3 20 mM in MEM with dialysed FCS, less NEA
CHO KI 15 mM in MEM with dialysed FCS
WEHI 164 20 mM in MEM
In all cases cells grow normally when 1 mM pyruvate is added. The
lowest concentration ofcarnosine tested was 20 mM, except in HeLa,
CHO and WEHI 164 cells.
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more sensitive to these high concentrations, especially in
MEM. The difference between DMEM and MEM is largely
attributable to the presence or absence of pyruvate, although
there is some effect of glucose (results not shown). MRC-5
grows somewhat more slowly in MEM containing 20 mM
carnosine without NEA. With substitution of 10% dialysed
FCS for normal FCS and in the absence of NEA, 20 mM
carnosine has a cytostatic effect. The non-growing cells retain
a normal fibroblast morphology for long periods. When these
cultures are returned to normal MEM, growth rapidly
resumes at the normal rate, indicating that there had been
little, if any, cell killing (results to be published elsewhere). In
contrast to the cytostatic effect of this medium on normal
cells, it is cytotoxic to transformed cells.
HeLa cells have a very variable heteroploid karyotype
resulting in the production of many slow-growing cells, or
cells with limited proliferative potential (Martinez et al.,
1978). This complicates the documentation of the cytotoxicity
of carnosine. In contrast, pseudo-diploid CHO cells produce
uniform rapidly growing colonies. The survival of CHO cells
treated with various levels of carnosine for 24 h in MEM
containing dialysed FCS and proline is shown in Figure 4.
HeLa cells show similar survival up to 20 mM carnosine, but
.3
L.
(aI
-
D- or L- carnosine (mM)
Figure 3 HeLa cells grown in 24-well trays for 4 days in MEM
supplemented with 10% FCS, NEA and the indicated levels of L-
carnosine or D-carnosine. W, 0-50 mM L-carnosine with 1 mM
sodium pyruvate. _, 0-50 mM L-carnosine without pyruvate.
( ) 20-50 mM D-carnosine with 1 mm sodium pyruvate. (1E )
30-50 mM D-carnosine without pyruvate. The star indicates no
measurement. Approximately 10 cells were inoculated per well
and the downward arrows indicate a cell yield lower than this.
Table III The ability of components of the tricarboxylic acid
(TCA) cycle to prevent inhibition by carnosine of HeLa cell growth,
in the absence of pyruvate
I mM sodium salt Growth in MEM with 20 mM carnosine
Oxaloacetate +
Citrate
Isocitrate
a-Ketoglutarate +
Succinate
Fumarate
Malate
Control (pyruvate) +
Alanine, glutamic acid and other components of the non-essential
amino acid supplement (serine, proline, aspartic acid, asparagine,
glycine) are inactive.
higher survival than CHO cells with 25 mM and 30 mM
carnosine. However, treatment with these concentrations for
48 and 72 h resulted in very low or no survival of HeLa cells.
Selection against HeLa cells
Since carnosine inhibits HeLa cells in a medium which allows
the survival of normal diploid cells, it should be possible to
select against HeLa cells in a mixed culture. Under normal
conditions HeLa cells proliferate rapidly in culture of MRC-
5, forming 'islands' or colonies of growth which are not
contact-inhibited (Figure 5). On further subculture, the HeLa
cells rapidly take over the population.
Approximately 103 HeLa cells were added to early passage
MRC-5 cells in MEM in 25 cm2 flasks. When the MRC-5
cells became confluent, the islands of HeLa could be clearly
seen. Thereafter the culture was treated with MEM contain-
ing dialysed FCS and 20 mM carnosine and subcultured in
this medium. The HeLa cells rapidly disappeared and did not
reappear when the MRC-5 cells were returned to normal
MEM without carnosine. Several protocols have been used to
eliminate HeLa cells successfully from these mixed cultures
and one which is characteristic is outlined in Figure 6. The
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Figure 4 The survival of CHO cells treated with various
concentrations of carnosine for 24h. *, MEM with 10%
dialysed serum and 1 mm proline. L, the same medium with
addition of 2 mm sodium pyruvate. The star indicates survival of
<0.02%. The results are the average survivals of two populations
for each treatment, except for the controls with pyruvate.
Figure 5 An 'island' of HeLa cells on a background of confluent
MRC-5 cells. MRC-5 cells were split 1:8 (3.8 x 105 cells) and
mixed with 103 HeLa cells in MEM in a 25 cm2 flask. After
incubation the MRC-5 cells became confluent, but the HeLa cells
form colonies or 'islands' which continue to proliferate.Inhibiton of tumour cells by carnosine
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Days
1 MRC-5 passage 27, 1:8 split (3.8 x 105 cells)
plus 103 HeLa cells in MEM
5 HeLa 'islands' appear (see Figure 5). Cells split
1:4 to MEM, with dialysed FCS and 20 mM carnosine
11-31 Two further subcultures (1:2 split) in same medium,
with three intervening changes of medium
32 No HeLa cells visible. Cells split to MEM
Subcultures in MEM
125 Senescence, with six subsequent weekly
changes of medium. HeLa cells absent
Figure 6 Procedure for eliminating HeLa cells from a mixture of
MRC-5 fibroblasts and HeLa.
MRC-5 cells were subcultured until they became senescent
and then the medium was changed weekly for 6 weeks. In no
case did the HeLa cells reappear.
In this experiment, the untreated mixed culture grew for
only 4 days before it was split and the cells transferred to
MEM with dialysed FCS and 20 mM carnosine. In other
experiments, the untreated mixed culture was split twice in
MEM (12 days growth) and many more HeLa cells were
present. To eliminate these cells, more subcultures in MEM
with dialysed FCS and 20 mM carnosine were required before
the HeLa cells disappeared (usually 5 -6 subcultures). Again,
the cells were finally returned to MEM and passaged until
senescent.
Discussion
Carnosine is widely distributed in human tissues with the
highest level of 20 mM in skeletal muscle (Mannion et al.,
1992). We previously showed that normal human fibroblasts
will grow well in standard media containing 20-30 mM
carnosine, and more slowly in 50 mM. In the course of these
studies we noticed that transformed cells did not grow in
MEM containing similar concentrations of carnosine,
whereas these cells grew vigorously in the same concentra-
tions in DMEM. We have investigated this difference and
extended the study to seven transformed or neoplastic human
cell lines and two rodent cell lines. All nine cell lines have a
similar response to carnosine. All grow in DMEM containing
20-50 mm carnosine, and all are inhibited in MEM or
RPMI containing carnosine.
DMEM is the richer medium with 0.45% glucose, non-
essential amino acids, elevated levels of some vitamins and
1 mM sodium pyruvate. The difference between the effect of
carnosine in MEM and DMEM can be very largely
attributed to the presence of pyruvate in the latter, although
there is some smaller effect of glucose concentration. The
results with RPMI, which does not contain pyruvate, are
similar to those with MEM. We have also shown that there is
a difference between MEM containing normal FCS and
MEM with dialysed FCS. This is in part due to pyruvate in
FCS, but there is a further interaction of pyruvate with
certain amino acids in FCS, which are absent in dialysed
FCS.
As a result of these studies, we have devised a medium
containing 20 mm carnosine and dialysed FCS which
inhibits growth and kills transformed cells, whilst allowing
normal cells to proliferate. We have used mixed cultures of
normal fibroblasts, strain MRC-5, and HeLa cells to show
that in the appropriate medium containing 20 mM carnosine,
the HeLa cells can be selectively eliminated (see Figure 6).
This procedure for the selection of normal cells and selection
against neoplastic cells has obvious implications that could
be exploited in various ways in future studies in vitro and in
vivo.
Pyruvate has a central place in metabolism. It is the end
product of anaerobic glycolysis and it is converted to acetyl
CoA which is the essential precursor of the tricarboxylic acid
(TCA) cycle for the aerobic generation ofATP. Pyruvate also
has an important role in amino acid and fatty acid
metabolism. Warburg (1930; 1956) discovered that tumour
cells have elevated glycolytic activity, leading to increased
lactic acid production from pyruvate. This is clearly a very
general phenomenon in a wide range of tumour cells
(Aisenberg, 1961). Warburg (1930, 1956) also proposed that
tumour cells are defective in aerobic respiration, but many
studies have shown that this is not the case (Weinhouse,
1995; Shapot, 1972; Dills, 1993). Nevertheless, tumour cells
depend more heavily on glycolysis than normal cells,
although the altered balance between anaerobic and aerobic
metabolism is not well understood (see Shapot, 1972; Dills,
1993).
The key role of pyruvate in metabolism provides a
possible explanation of the carnosine toxicity to tumour
cells. It has been shown that the terminal amino group of
carnosine reacts strongly with aldehyde and keto groups of
sugars. This is the Amadori reaction that is involved in the
non-enzymic glycosylation of proteins and the subsequent
production, via the Maillard reaction, of advanced glycation
end products (AGEs, reviewed by Monnier 1988). Carnosine
reacts more strongly than lysine with various sugars and it
has been suggested that its role in the cell is to act as a
competitive inhibitor of non-enzymic glycosylation of
proteins (Michaelis et al., 1992; Hipkiss et al., 1994, 1995).
Furthermore, it has been shown that carnosine reacts rapidly
with the triose phosphate sugar intermediates of glycolysis,
particularly glyceraldehyde phosphate and dihydroxyacetone
phosphate (A Stevens, personal communication). From
experiments with 3H-labelled carnosine, we know that
carnosine is taken up from the medium (unpublished
results). Our interpretation of its effects on tumour cells is
that it depletes glycolysis intermediates, reduces production
of pyruvate by glycolysis and therefore reduces the generation
of ATP by this anaerobic pathway. The reduced pyruvate
would also limit the production of ATP by the TCA cycle.
The end result, we propose, is that the cells have insufficient
energy for growth and survival. This whole effect is
completely reversed by the addition of pyruvate to the
medium. Normal cells are much more tolerant of carnosine
possibly because they are less dependent on glycolysis for
energy supply and can better regulate glycolysis in relation to
aerobic respiration. Although we have as yet no direct
evidence for our interpretation, it is strongly supported by
experiments with another compound which reacts with
sugars, known as tenilsetam, (±)-3-(2-thienyl)-2-piperazi-
none (Munch et al., 1994). An concentration of 10 mM
tenilsetam in MEM is cytotoxic to HeLa cells, but this effect
is reversed by pyruvate. This remarkable result (to be
published elsewhere) on the specificity and extent of thefn dhiltm of nour cds by w- nsm
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'pyruvate effect', reinforces and strengthens our hypothesis.
Nevertheless, we have as yet no direct evidence that carnosine
reacts with glycolysis intermediates in vivo.
We have shown that the naturally occurring dipeptide
anserine (which is derived from carnosine by the enzymic
methylation of histidine) is also effective in inhibiting tumour
cells, whereas homocarnosine is without effect. We have also
shown that D-carnosine is non-inhibitory, even at 50 mM in
the absence of pyruvate, and presume that it is not actively
incorporated into cells. We have also examined the effect of
TCA cycle components on carnosine inhibition of tumour
cells. Oxaloacetate and x-ketoglutarate have an effect
comparable to pyruvate, but the other intermediates are
inactive in our assay. This result is not obviously explained
by uptake or lack of uptake into the mitochondria, but may
relate more to the important role of x-ketoglutarate and
oxaloacetate, as well as pyruvate, in amino acid metabolism.
We have shown that in the absence of alanine and glutamic
acid, considerably more pyruvate is necessary to prevent
carnosine toxicity, presumably because a proportion of the
pyruvate produced by glycolysis is necessary for amino acid
and protein synthesis.
We have previously proposed that carnosine may have an
important role in cellular homeostasis. It significantly reduces
the normal features of senescence of late passage human
fibroblasts and may extend their lifespan in population
doublings. Part of this effect may be due to the prevention
ofnon-enzymic glycosylation ofproteins, but other metabolic
effects could also be important. The functions of carnosine
would be integrated into normal metabolic processes, but in
tumour cells with abnormal metabolism its particular
properties appear to be disastrous for the cell, at least in
the absence of pyruvate or two TCA intermediates. In his
book 'The Glycolysis and Respiration of Tumours' Aisenberg
(1961) concludes by suggesting that chemotherapeutic attack
on tumour cells could take place through an agent that acted
on the limited respiratory enzymes of the neoplastic cell 'or
through an agent which attacked the glycolytic mechanism
(perhaps on the assumption that the high rate of glycolysis
was uniquely necessary for the neoplastic process)'. If this
assumption is correct, and carnosine does indeed interfere
with glycolysis, then it may have value as a therapeutic agent,
especially if this can be combined with treatments which
greatly decrease normal levels of pyruvate and related
metabolites.
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